Management of Reactive FTA-ABS with Non-Reactive RPR
Understanding This Serologic Pattern
- The combination of reactive treponemal test (FTA-ABS) with non-reactive nontreponemal test (RPR) most commonly represents late latent or tertiary syphilis, previously treated syphilis, or false-positive treponemal test 1
- Nontreponemal tests like RPR have significantly reduced sensitivity in late-stage disease, with sensitivity dropping to only 30.7-56.9% in previously treated syphilis and 47-76% in late latent/tertiary syphilis 3, 2
Treatment Algorithm
- The American College of Physicians recommends treating patients with benzathine penicillin G 2.4 million units IM once weekly for 3 weeks for presumed late latent syphilis, unless adequate prior treatment is documented 1
- If treatment history is uncertain, inadequate, or absent, proceed immediately to treatment for late latent syphilis with benzathine penicillin G 2.4 million units IM once weekly for 3 weeks 2
Assessment for Active Disease
- The Centers for Disease Control and Prevention recommends evaluating for clinical signs that would change management, including neurologic symptoms, ocular symptoms, new chancre or mucocutaneous lesions, and cardiovascular symptoms 2
- If any red flags are present, perform lumbar puncture for CSF examination to rule out neurosyphilis, and consider CSF VDRL and CSF leukocyte count >5 WBCs/mm³ as diagnostic indicators for neurosyphilis 2, 1, 4
HIV Testing and Special Considerations
- The American Academy of HIV Medicine recommends that all patients with syphilis be tested for HIV, as HIV-infected patients may have atypical serologic patterns and require more frequent monitoring 2
- For patients with penicillin allergy, penicillin desensitization is strongly preferred for late latent syphilis, while doxycycline 100 mg orally twice daily for 14 days can be used for early syphilis only 2
Follow-Up Recommendations
- Clinical follow-up is recommended for newly diagnosed and treated late latent syphilis, though serologic response may be minimal, and many patients will remain "serofast" with persistent low-level RPR titers (<1:8) for life 1, 2